🚀 VC round data is live in beta, check it out!
Journey Medical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Journey Medical and similar public comparables like Vytrus Biotech, Oramed Pharmaceuticals, Medivir, Alpha Cognition and more.
Journey Medical Overview
About Journey Medical
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Founded
2014
HQ
Employees
41
Website
Sectors
Financials (LTM)
EV
$143M
Journey Medical Financials
Journey Medical reported last 12-month revenue of $68M and EBITDA of $6M.
In the same LTM period, Journey Medical generated $43M in gross profit, $6M in EBITDA, and had net loss of ($8M).
Revenue (LTM)
Journey Medical P&L
In the most recent fiscal year, Journey Medical reported revenue of $62M and EBITDA of $3M.
Journey Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $68M | XXX | $62M | XXX | XXX | XXX |
| Gross Profit | $43M | XXX | $41M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $6M | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 5% | XXX | XXX | XXX |
| EBIT Margin | (6%) | XXX | (13%) | XXX | XXX | XXX |
| Net Profit | ($8M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | (12%) | XXX | (18%) | XXX | XXX | XXX |
| Net Debt | — | — | $1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Journey Medical Stock Performance
Journey Medical has current market cap of $142M, and enterprise value of $143M.
Market Cap Evolution
Journey Medical's stock price is $5.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $143M | $142M | -3.0% | XXX | XXX | XXX | $-0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJourney Medical Valuation Multiples
Journey Medical trades at 2.1x EV/Revenue multiple, and 25.7x EV/EBITDA.
EV / Revenue (LTM)
Journey Medical Financial Valuation Multiples
As of April 11, 2026, Journey Medical has market cap of $142M and EV of $143M.
Equity research analysts estimate Journey Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Journey Medical has a P/E ratio of (18.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $142M | XXX | $142M | XXX | XXX | XXX |
| EV (current) | $143M | XXX | $143M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 25.7x | XXX | 49.8x | XXX | XXX | XXX |
| EV/EBIT | (36.9x) | XXX | (17.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | 3.5x | XXX | XXX | XXX |
| P/E | (18.1x) | XXX | (12.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (11.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Journey Medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Journey Medical Margins & Growth Rates
Journey Medical's revenue in the last 12 month grew by 46%.
Journey Medical's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $1.2M for the same period.
Journey Medical's rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Journey Medical's rule of X is 107% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Journey Medical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 46% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 236% | XXX | 342% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 107% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 32% | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 35% | XXX | 37% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Journey Medical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vytrus Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Oramed Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Medivir | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| Humacyte | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Journey Medical M&A Activity
Journey Medical acquired XXX companies to date.
Last acquisition by Journey Medical was on XXXXXXXX, XXXXX. Journey Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Journey Medical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJourney Medical Investment Activity
Journey Medical invested in XXX companies to date.
Journey Medical made its latest investment on XXXXXXXX, XXXXX. Journey Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Journey Medical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Journey Medical
| When was Journey Medical founded? | Journey Medical was founded in 2014. |
| Where is Journey Medical headquartered? | Journey Medical is headquartered in United States. |
| How many employees does Journey Medical have? | As of today, Journey Medical has over 41 employees. |
| Who is the CEO of Journey Medical? | Journey Medical's CEO is Claude Maraoui. |
| Is Journey Medical publicly listed? | Yes, Journey Medical is a public company listed on Nasdaq. |
| What is the stock symbol of Journey Medical? | Journey Medical trades under DERM ticker. |
| When did Journey Medical go public? | Journey Medical went public in 2021. |
| Who are competitors of Journey Medical? | Journey Medical main competitors are Vytrus Biotech, Oramed Pharmaceuticals, Medivir, Alpha Cognition. |
| What is the current market cap of Journey Medical? | Journey Medical's current market cap is $142M. |
| What is the current revenue of Journey Medical? | Journey Medical's last 12 months revenue is $68M. |
| What is the current revenue growth of Journey Medical? | Journey Medical revenue growth (NTM/LTM) is 46%. |
| What is the current EV/Revenue multiple of Journey Medical? | Current revenue multiple of Journey Medical is 2.1x. |
| Is Journey Medical profitable? | Yes, Journey Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Journey Medical? | Journey Medical's last 12 months EBITDA is $6M. |
| What is Journey Medical's EBITDA margin? | Journey Medical's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Journey Medical? | Current EBITDA multiple of Journey Medical is 25.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.